Lead Product(s) : Vamifeport
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Enrolled in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease
Details : VIT-27639 (Vamifeport), is the first oral ferroportin inhibitor investigated for treatment of diseases with ineffective production of red blood cells and iron overload such as sickle cell disease.
Product Name : VIT-2763
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2021
Lead Product(s) : Vamifeport
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable